Synopsis
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Ambroxol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ambroxol Hydrochloride manufacturer or Ambroxol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ambroxol Hydrochloride manufacturer or Ambroxol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ambroxol Hydrochloride API Price utilized in the formulation of products. Ambroxol Hydrochloride API Price is not always fixed or binding as the Ambroxol Hydrochloride Price is obtained through a variety of data sources. The Ambroxol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ambrohexal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ambrohexal, including repackagers and relabelers. The FDA regulates Ambrohexal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ambrohexal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ambrohexal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ambrohexal supplier is an individual or a company that provides Ambrohexal active pharmaceutical ingredient (API) or Ambrohexal finished formulations upon request. The Ambrohexal suppliers may include Ambrohexal API manufacturers, exporters, distributors and traders.
click here to find a list of Ambrohexal suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ambrohexal DMF (Drug Master File) is a document detailing the whole manufacturing process of Ambrohexal active pharmaceutical ingredient (API) in detail. Different forms of Ambrohexal DMFs exist exist since differing nations have different regulations, such as Ambrohexal USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ambrohexal DMF submitted to regulatory agencies in the US is known as a USDMF. Ambrohexal USDMF includes data on Ambrohexal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ambrohexal USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ambrohexal suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ambrohexal Drug Master File in Japan (Ambrohexal JDMF) empowers Ambrohexal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ambrohexal JDMF during the approval evaluation for pharmaceutical products. At the time of Ambrohexal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ambrohexal suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ambrohexal Drug Master File in Korea (Ambrohexal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ambrohexal. The MFDS reviews the Ambrohexal KDMF as part of the drug registration process and uses the information provided in the Ambrohexal KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ambrohexal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ambrohexal API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ambrohexal suppliers with KDMF on PharmaCompass.
A Ambrohexal CEP of the European Pharmacopoeia monograph is often referred to as a Ambrohexal Certificate of Suitability (COS). The purpose of a Ambrohexal CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ambrohexal EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ambrohexal to their clients by showing that a Ambrohexal CEP has been issued for it. The manufacturer submits a Ambrohexal CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ambrohexal CEP holder for the record. Additionally, the data presented in the Ambrohexal CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ambrohexal DMF.
A Ambrohexal CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ambrohexal CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ambrohexal suppliers with CEP (COS) on PharmaCompass.
A Ambrohexal written confirmation (Ambrohexal WC) is an official document issued by a regulatory agency to a Ambrohexal manufacturer, verifying that the manufacturing facility of a Ambrohexal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ambrohexal APIs or Ambrohexal finished pharmaceutical products to another nation, regulatory agencies frequently require a Ambrohexal WC (written confirmation) as part of the regulatory process.
click here to find a list of Ambrohexal suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ambrohexal as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ambrohexal API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ambrohexal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ambrohexal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ambrohexal NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ambrohexal suppliers with NDC on PharmaCompass.
Ambrohexal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ambrohexal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ambrohexal GMP manufacturer or Ambrohexal GMP API supplier for your needs.
A Ambrohexal CoA (Certificate of Analysis) is a formal document that attests to Ambrohexal's compliance with Ambrohexal specifications and serves as a tool for batch-level quality control.
Ambrohexal CoA mostly includes findings from lab analyses of a specific batch. For each Ambrohexal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ambrohexal may be tested according to a variety of international standards, such as European Pharmacopoeia (Ambrohexal EP), Ambrohexal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ambrohexal USP).
